


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) ~~Use of the compounds of the following formula (I):~~ A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I):



wherein X represents OH, (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂;

R₁ is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C₁₋₅) alkoxy groups, (C₁₋₅) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile;

R₂ is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and or Pro;

Y₁ and Y₂ independently from each other represent H or (C₁₋₅) alkyl;

R₃ and R₄ independently from each other represent H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy; and

R₅ represents H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy;

or a pharmaceutically acceptable salt thereof;

~~for the preparation of a medicament useful in the treatment of neurodegenerative diseases.~~

2. (currently amended) The use method according to claim 1, wherein x represents (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂.

3. (currently amended) The use method according to claim 1 or 2, wherein R₃ and R₄ independently from each other represent H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not (C₁₋₅) alkoxy.

4. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₅ represents H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy.

5. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

6. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein the neurodegenerative disease is mild cognitive impairment.


7. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₁ is a residue which is derived from one of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom or which is derived from Ile.

8. (currently amended) The use method according to claim 7, wherein R₁ is a residue which is derived from Phe, which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom.

9. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₂ is a residue which is derived from the amino acid Gly or Ile.

10. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

11. (currently amended) A pharmaceutical ~~Pharmaceutical~~ composition comprising compounds of the following formula (I):



(I)

wherein X represents OH, (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, N(C₁₋₅ alkyl)₂;

R₁ is a residue derived from one of the amino acids Phe, which each may be optionally substituted with one or more (C₁₋₅) alkoxy groups, (C₁₋₅) alkyl groups or halogen atoms;

R₂ is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro;

Y₁ and Y₂ independently from each other represent H or (C₁₋₅) alkyl;

R₃ and R₄ independently from each other represent H, OH, (C₁₋₅) alkyl or (C₁₋₅)alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy; and

R₅ represents H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy;

or a pharmaceutically acceptable salt thereof ;

and pharmaceutically acceptable excipients.

12. (currently amended) ~~The pharmaceutical~~ The pharmaceutical composition according to claim 11, wherein x represents (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅ alkyl or N(C₁₋₅ alkyl)₂.

13. (currently amended) ~~The pharmaceutical~~ The pharmaceutical composition according to claims 11 or 12, wherein R₂ is a residue which is derived from the amino acid Gly.

14. (currently amended) ~~The pharmaceutical~~ The pharmaceutical composition according to ~~claims claim~~ claim 11 to 13, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucylphenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucylisoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

15. (canceled)